JPRN-UMIN000011362已完成2 期
Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancer - Phase II study of biweekly cetuximab+irinotecan therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •severe dysfunction of bone marrow, liver, renal, and cardiac function; prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co-existing malignancy or malignancy within the last five years prior to enrollment ; no severe concurrent medical or psychiatric illness; no a known hypersensitivity to the study drugs; and none of the patients were pregnant or lactating.
研究者
相似试验
招募中
2 期
Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix studycolorectal cancerJPRN-UMIN000003483Kitasato University East Hospital Department of gastroenterological surgery, Department of gastroenterology38
已完成
2 期
Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancerMetastatic colorectal cancerJPRN-UMIN000019893The Cancer Institute Hospital, Japanese Foundation for Cancer Research35
已完成
2 期
Phase II study of biweekly cetuximab plus irinotecan for unresectable colorectal cancerJPRN-UMIN000001951Aichi Cancer Center Hospital30
已完成
2 期
Phase II study of cetuximab plus irinotecan for unresectable colorectal cancernresectable advaned or recurrent colorectal cancerJPRN-UMIN000001838Aichi Cancer Center Hospital30
招募中
2 期
Phase II trial of irinotecan with biweekly cetuximab in unresectable advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on EGFR positive and KRAS wild type.(i-BEX trial)advanced/metastatic colorectal cancerJPRN-UMIN000002761PO FMPC (Future Medicine Promoting Consortium)45